WP
HRMY icon

Woodline Partners’s Harmony Biosciences HRMY Stock Holding History

Woodline Partners’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-181,824
Closed -$6.03M – 982
2025
Q1 		$6.03M Buy
+181,824
New +$6.52M 0.04% 453
2024
Q1 		– Sell
-149,518
Closed -$4.83M – 582
2023
Q4 		$4.83M Sell
149,518
-84,341
-36% -$2.35M 0.05% 322
2023
Q3 		$7.66M Sell
233,859
-6,357
-3% -$221K 0.09% 251
2023
Q2 		$8.45M Buy
+240,216
New +$8.29M 0.1% 227

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's HRMY Position: Q2 2025 in Review

Woodline Partners sold out of Harmony Biosciences (HRMY) in Q2 2025, closing a stake of 181,824 shares — an estimated $6.03M sold.

Woodline Partners first reported a position in HRMY in Q2 2023 and held it in 4 quarters. The position peaked at $8.45M in Q2 2023. 279 funds tracked by Wall St. Rank hold HRMY as of Q2 2025.

  • Woodline Partners reported no remaining Harmony Biosciences position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 181,824 Harmony Biosciences shares in Q2 2025, an estimated $6.03M.
  • Woodline Partners first reported a position in Harmony Biosciences in Q2 2023 and held it in 4 quarters.
  • Woodline Partners's Harmony Biosciences position peaked at $8.45M in Q2 2023.
  • 279 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.